These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 12034047)

  • 21. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy.
    Fukutomi T; Nakamuta M; Fukutomi M; Iwao M; Watanabe H; Hiroshige K; Tanabe Y; Nawata H
    J Hepatol; 2001 Jan; 34(1):100-7. PubMed ID: 11211884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal transplant recipient with chronic hepatitis C who obtained sustained viral response after interferon-beta therapy.
    Konishi I; Horiike N; Michitaka K; Ochi N; Furukawa S; Minami H; Onji M
    Intern Med; 2004 Oct; 43(10):931-4. PubMed ID: 15575242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-beta for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study.
    Kainuma M; Ogata N; Kogure T; Kohta K; Hattori N; Mitsuma T; Terasawa K
    Phytomedicine; 2002 Jul; 9(5):365-72. PubMed ID: 12222653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation between serum hepatitis C virus-RNA levels and efficacy of interferon-beta therapy.
    Minohara Y; Kato T; Kanki K; Goshima T; Nakajima N; Kaku H; Arimoto Y; Goshima F; Ishiko H
    Acta Paediatr Jpn; 1995 Aug; 37(4):530-3. PubMed ID: 7572160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerance and efficacy of subcutaneous interferon-beta administered for treatment of chronic hepatitis C.
    Castro A; Carballo E; Domínguez A; Diago M; Suárez D; Quiroga JA; Carreño V
    J Interferon Cytokine Res; 1997 Feb; 17(2):65-7. PubMed ID: 9058311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of a serotype-1 hepatitis C virus infection using interferon-beta in a patient with a high RNA titer who had been receiving long-term hemodialysis therapy.
    Otsubo S; Kawata T; Takasaki M; Ishihara M; Ueda S; Sugimoto H; Otsubo K; Akiba T; Nitta K; Hirano M
    Intern Med; 2011; 50(7):733-7. PubMed ID: 21467707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative analysis of p40/p46 and p69/p71 forms of 2',5'-oligoadenylate synthetase mRNA by competitive PCR and its clinical application.
    Takahashi A; Iwasaki Y; Miyaike J; Taniguchi H; Shimomura H; Hanafusa T; Yumoto Y; Moriya A; Koide N; Tsuji T
    Clin Chem; 2002 Sep; 48(9):1551-9. PubMed ID: 12194933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Optimal virologic monitoring of hepatitis C in 2009: Treatment duration depends on the speed of virologic response and the duration of the negative reaction].
    Halfon P; Ouzan D
    Presse Med; 2009; 38(7-8):1037-40. PubMed ID: 19157775
    [No Abstract]   [Full Text] [Related]  

  • 29. Current progress in antiviral strategies.
    Lou Z; Sun Y; Rao Z
    Trends Pharmacol Sci; 2014 Feb; 35(2):86-102. PubMed ID: 24439476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is interferon-beta an alternative treatment for chronic hepatitis C?
    Moreno-Otero R; Trapero-Marugán M; Gómez-Domínguez E; García-Buey L; Moreno-Monteagudo JA
    World J Gastroenterol; 2006 May; 12(17):2730-6. PubMed ID: 16718760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-beta treatment are predictive of long-term therapeutic response.
    Enomoto M; Nishiguchi S; Tanaka M; Fukuda K; Ueda T; Tamori A; Habu D; Takeda T; Shiomi S; Yano Y; Otani S
    J Interferon Cytokine Res; 2002 Mar; 22(3):389-95. PubMed ID: 12034047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment.
    Enomoto M; Nishiguchi S; Shiomi S; Tanaka M; Yokogawa T; Fukuda K; Ueda T; Tamori A; Habu D; Takeda T; Yano Y; Otani S
    Am J Gastroenterol; 2002 Feb; 97(2):420-6. PubMed ID: 11866282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
    Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
    Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
    J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.